An investigational induced pluripotent stem cell-derived CAR natural killer cell therapy was well tolerated both as ...

Patients with relapsed or refractory large B-cell lymphoma who received epcoritamab or glofitamab in real-world settings ...

High-grade CBCLs often recur (come back) even after treatment ... Lymphoma Research Foundation. Cutaneous B-cell lymphoma. National Cancer Institute. Tumor grade. American Cancer Society. Lymphoma of ...

30% had de novo diffuse large B-cell lymphoma, 17% had low-grade follicular lymphoma, 8% had transformed indolent non-Hodgkin lymphoma or grade 3B follicular lymphoma, 6% had high-grade B-cell ...

Dark zone lymphoma includes aggressive B-cell lymphomas with shared molecular features. While some respond to escalated ...

Bristol Myers Squibb Canada (BMS) is pleased to announce Health Canada's approval of Breyanzi® (lisocabtagene maraleucel), a type of chimeric antigen receptor T cell (CAR T) therapy, for the treatment ...

AstraZeneca's CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas and — due to innovations in manufacturing — could make future cellular ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas ... the CAR-NK cells to lymphoma cells. A total of 10 study participants experienced low-grade cytokine release syndrome ...

They are generally classified according to the cancer's growth rate as high grade (fast growing ... of genetic subtypes in diffuse large B-cell lymphoma not otherwise specified (DLBCL-NOS ...

Loncastuximab tesirine is a CD19-directed antibody and alkylating agent currently FDA-approved to treat refractory or relapsed large B-cell lymphoma in adults ... for loncastuximab tesirine phase 2 ...